Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Stella

Recruiting

Back to Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(8 sites)

United States

Florida Cancer Specialists, Sarasota, Florida

University Medical Center - New Orleans, New Orleans, Louisiana

Dana-Farber Cancer Institute, Boston, Massachusetts

START - Midwest, Grand Rapids, Michigan

SCRI Oncology Partners, Nashville, Tennessee

Key details

Phase

Early testing

Sponsor

Olema Pharmaceuticals, Inc.

Enrollment target

~180 participants

Started

December 2024

Primary completion

May 2027

Age range

18 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov